Promoting clinical benefits of an interchangeable over standard biosimilars is likely to be considered false and misleading by the FDA • Source: Shutterstock
Stay ahead of every shift in generics and biosimilars.
Generics Bulletin brings you the latest updates that matter for the off-patent industry.
